Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes.

ABSTRACT:

Aim

To investigate whether an increased bolus: basal insulin ratio (BBR) with liver-targeted bolus insulin (BoI) would increase BoI use and decrease hypoglycaemic events (HEv).

Patient population and methods

We enrolled 52 persons (HbA1c 6.9% ± 0.12%, mean ± SEM) with type 1 diabetes using multiple daily injections. Hepatic-directed vesicle (HDV) was used to deliver 1% of peripheral injected BoI to the liver. A 90-day run-in period was used to introduce subjects to unblinded continuous glucose monitoring and optimize standard basal insulin (BaI) (degludec) and BoI (lispro) dosing. At 90 days, BoI was changed to HDV-insulin lispro and subjects were randomized to an immediate 10% or 40% decrease in BaI dose.

Results

At 90 days postrandomization, total insulin dosing was

SUBMITTER: Weinstock RS 

PROVIDER: S-EPMC9546184 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature